MYNZ

Mainz Biomed N.V

Oct 21 • 04:00PM ET

1.55

-0.01 -0.64 %

Healthcare • Diagnostics & Research • Germany • NASD

Peers: ILMN EXAS NTRA GH FLGT QGEN CDNA OCGN AXDX TRIB

Index	-	P/E	-	EPS (ttm)	-	Insider Own	3.35%	Shs Outstand	5.41M	Perf Week	0.65%
Market Cap	8.39M	Forward P/E	-	EPS next Y	-1.35	Insider Trans	0.00%	Shs Float	5.23M	Perf Month	-4.91%
Enterprise Value	9.57M	PEG	-	EPS next Q	-	Inst Own	7.12%	Short Float	1.71%	Perf Quarter	-25.48%
Income	-	P/S	-	EPS this Y	87.21%	Inst Trans	1.65%	Short Ratio	0.38	Perf Half Y	-51.41%
Sales	-	P/B	4.84	EPS next Y	52.80%	ROA	-	Short Interest	0.09M	Perf YTD	-64.12%
Book/sh	0.32	P/C	4.39	EPS next 5Y	59.64%	ROE	-	52W High	14.39 -89.23%	Perf Year	-87.00%
Cash/sh	0.35	P/FCF	-	EPS past 3/5Y	29.88% -52.02%	ROIC	-	52W Low	1.28 21.08%	Perf 3Y	-99.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	15.69% 16.01%	Gross Margin	-	Volatility	8.60% 9.11%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	11.95%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.27	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.52	EPS Q/Q	-1121.45%	SMA20	-0.58%	Beta	0.25	Target Price	14.00
Payout	-	Debt/Eq	1.23	Sales Q/Q	-	SMA50	-4.70%	Rel Volume	0.73	Prev Close	1.56
Employees	26	LT Debt/Eq	0.44	Earnings	Sep 03	SMA200	-47.78%	Avg Volume	238.16K	Price	1.55
IPO	Nov 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	175,802	Change	-0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Initiated	Maxim Group	Buy	$14
Nov-25-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-21-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-21-22	Initiated	H.C. Wainwright	Buy	$25

Oct-15-25 09:01AM	Mainz Biomed to Attend 2025 Maxim Growth Summit (GlobeNewswire)
Oct-08-25 09:00AM	Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project (GlobeNewswire)
Sep-30-25 08:01AM	Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting (GlobeNewswire)
Sep-23-25 08:01AM	Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland (GlobeNewswire)
Sep-02-25 08:01AM	Mainz Biomed Announces Registration of ColoAlert in the United Kingdom (GlobeNewswire)
08:01AM	Loading…
Aug-13-25 08:01AM	Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert (GlobeNewswire) +17.01%
Aug-04-25 10:22AM	Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants (GlobeNewswire) +6.77%
Jul-23-25 08:01AM	Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies (GlobeNewswire)
Jul-15-25 08:01AM	Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition (GlobeNewswire) +7.03%
Jun-25-25 08:01AM	Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test (GlobeNewswire)
Jun-11-25 06:42AM	Mainz begins next phase of project to develop pancreatic cancer blood test (Medical Device Network)
Jun-10-25 09:01AM	Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project (GlobeNewswire)
May-21-25 06:00AM	Will AI Empower the PR Industry or Create Endless Seas of Spam? (The Wall Street Journal) -10.30%
May-19-25 08:01PM	Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants (GlobeNewswire) -9.43% +5.43%
May-16-25 08:01AM	Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study (GlobeNewswire) +7.49%
08:01AM	Loading…
Apr-29-25 08:01AM	Mainz Biomed Enters into Technology Partnership with EDX Medical Group (GlobeNewswire)
Apr-28-25 08:01AM	Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval (GlobeNewswire)
Apr-01-25 08:01AM	Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.72%
Mar-28-25 06:49AM	Mainz enrols first subject in study to evaluate colorectal cancer test (Medical Device Network) -9.78%
Mar-27-25 09:01AM	Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study (GlobeNewswire) -7.07%
Mar-20-25 10:35AM	Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates (Zacks) +12.41%
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-13-25 08:01AM	Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer (GlobeNewswire)
Mar-03-25 08:01AM	Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention (GlobeNewswire)
Feb-20-25 08:01AM	Mainz Biomed Expands into Switzerland with labor team w (GlobeNewswire) +7.28%
Feb-11-25 08:01AM	Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month (GlobeNewswire) +11.28%
Jan-27-25 08:01AM	Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements (GlobeNewswire) +10.79%
Jan-21-25 08:01AM	Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population (GlobeNewswire)
Dec-20-24 10:31AM	Mainz Biomed partners with Quest for colorectal cancer screening test (Medical Device Network) +40.04%
Dec-19-24 08:01AM	Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test (GlobeNewswire) +26.19%
05:00PM	Loading…
Dec-16-24 05:00PM	Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering (GlobeNewswire) -11.69% -6.62%
Dec-12-24 08:00PM	Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules (GlobeNewswire) +6.26%
Nov-29-24 08:45AM	Mainz Biomed Announces Stock Split (GlobeNewswire) -14.06%
Nov-13-24 07:23PM	The Oncology Bet Is Already Paying Off For Pfizer (Benzinga) -9.65%
Nov-12-24 09:00AM	Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets (GlobeNewswire) +28.70%
Oct-22-24 08:10AM	Mainz Biomed restructured operations, implemented cost reductions (TipRanks) +5.09%
Oct-21-24 08:01AM	Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-10-24 05:37PM	Mainz Biomed Secures Additional $1.5M Funding (TipRanks) -13.95%
Oct-08-24 08:01AM	Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version (GlobeNewswire) +7.61%
Oct-01-24 02:11PM	The Covid Era Tech Promises To Reinvent Cancer Treatment (Benzinga)
08:01AM	Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 (GlobeNewswire)
Sep-20-24 10:48AM	Pfizer Advances On Its Cancer Journey (Benzinga)
Sep-18-24 08:01AM	Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador (GlobeNewswire) -7.36%
Sep-04-24 04:01AM	Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert (GlobeNewswire) -9.39%
Jul-30-24 12:09PM	Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer (Benzinga)
Jul-25-24 08:01AM	Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience (GlobeNewswire)
Jul-19-24 12:38PM	Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test (News Direct) -8.16%
Jul-10-24 04:12AM	Mainz Biomed seeks FDA breakthrough device status for colorectal cancer test (Medical Device Network) -15.52%
Jul-09-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
03:01AM	Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test (GlobeNewswire)
Jul-02-24 01:38PM	mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment (Benzinga)
08:01AM	Mainz Biomed Provides Half Year 2024 Corporate Update (GlobeNewswire)
Jun-04-24 01:45PM	Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon (Benzinga) -16.36%
Jun-03-24 08:01AM	Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 (GlobeNewswire)
May-31-24 05:01PM	Mainz Biomed Reports Results of 2024 Annual General Meeting (GlobeNewswire) +20.39%
May-29-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-28-24 08:01AM	Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting (GlobeNewswire) +32.94%
May-20-24 08:01AM	Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial (GlobeNewswire) -9.03%
May-17-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +5.90%
May-16-24 10:51AM	Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game (Benzinga)
May-07-24 08:01AM	Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. (GlobeNewswire) +5.97%
Apr-29-24 12:02PM	mRNA Is Promising A Breakthrough In Fighting Cancer (Benzinga) +5.98%
Apr-25-24 09:29AM	Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic (GlobeNewswire)
Apr-10-24 12:47PM	The Pharmaceutical Industry Finds Itself At A Historical Crossroads (Benzinga) +6.06%
Apr-09-24 09:53PM	MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.33%
08:01AM	Mainz Biomed Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 08:01AM	Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment (GlobeNewswire)
Mar-18-24 08:01AM	Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options (GlobeNewswire)
Mar-12-24 08:01AM	Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations (GlobeNewswire)
Mar-08-24 12:00PM	What Makes Mainz Biomed NV (MYNZ) a New Buy Stock (Zacks)
Mar-05-24 08:01AM	Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic (GlobeNewswire)
Feb-28-24 12:54PM	Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening (Benzinga)
Feb-27-24 08:01AM	Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community (GlobeNewswire) -5.70%
Feb-22-24 02:21PM	Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment (Benzinga)
08:01AM	Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® (GlobeNewswire)
Feb-21-24 08:01AM	Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy (GlobeNewswire)
Feb-07-24 12:13PM	2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front (Benzinga)
Feb-06-24 08:01AM	Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany (GlobeNewswire)
Feb-01-24 04:17PM	Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle (Benzinga) -7.89%
Jan-11-24 08:01AM	Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gda sk Gastroenterology Symposium (GlobeNewswire)
Jan-09-24 03:40PM	2024 Marks a New Era Of Pharmaceutical Innovation (Benzinga)
08:01AM	Mainz Biomed Provides Year-End Corporate Review 2023 (GlobeNewswire)
Dec-29-23 02:48PM	2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer (Benzinga)
Dec-19-23 08:01AM	Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees (GlobeNewswire)
Dec-12-23 08:01AM	Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland (GlobeNewswire)
Dec-05-23 02:06PM	While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer (Benzinga) -24.53%
09:01AM	Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers (GlobeNewswire)
Nov-29-23 08:01AM	Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast (GlobeNewswire)
Nov-20-23 08:01AM	Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-16-23 08:01AM	Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-15-23 09:01AM	Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering (GlobeNewswire)
Nov-13-23 09:00AM	Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering (GlobeNewswire) -46.43%
Nov-09-23 08:01AM	Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test (GlobeNewswire) -17.14%
Nov-07-23 08:01AM	Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA (GlobeNewswire) +13.45%
Nov-01-23 08:40AM	Why Is Mainz Biomed (MYNZ) Stock Moving Today? (InvestorPlace)
Oct-31-23 08:01AM	Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Z ller-Kipper (GlobeNewswire)
Oct-26-23 08:01AM	Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations (GlobeNewswire)
Oct-18-23 08:01AM	Mainz Biomed Presents Groundbreaking Results of ColoFuture Study (GlobeNewswire)
Oct-17-23 03:16PM	Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine (Benzinga)
Oct-11-23 08:01AM	Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark (GlobeNewswire)

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MYNZ

Mainz Biomed N.V

Upgrade your FINVIZ experience